220723

Moderate to Severe Atopic Dermatitis Research Trial – (264 Weeks)


Age: 18 Years



Participating Locations

No Clinics Found

Participating Experts

No Doctors Found

You May Also Be Interested In

Similar Trials

No Similar Trials Found

The following information is from ClinicalTrials.gov

Last Update Posted: July 16, 2024

Official Title

Long-Term Extension Study (AtDvance) to Evaluate the Safety and Efficacy of GSK1070806 in Participants With Moderate to Severe Atopic Dermatitis.

ClinicalTrials.gov ID

NCT06447506

Sponsor

GlaxoSmithKline

Study Description

  • Brief Summary:

    The study is designed to evaluate the long-term safety and efficacy of GSK1070806 in participants with moderate-to severe atopic dermatitis, who have completed phase 2b parent GSK atopic dermatitis (AtD) study (NCT05999799).

  • Condition or Disease:

    Dermatitis, Atopic

  • Intervention/Treatment:

    Drug: GSK1070806 Drug: GSK1070806 Drug: GSK1070806 Drug: GSK1070806
  • Phase:

    PHASE2

  • Ages Eligible for Study:

    18 Years and older (ADULT,OLDER_ADULT)

  • Sexes Eligible for Study:

    ALL


Terms and Conditions – ClinicalTrials.gov
Purpose of ClinicalTrials.gov Database. The U.S. National Institutes of Health, Department of Health and Human Services, through its National Library of Medicine, has developed ClinicalTrials.gov to provide patients, family members, and members of the public current information about clinical research studies.



about-icon

Learn More About

ECZEMA - ATOPIC DERMATITIS

Learn More
2025 all rights reserved Probity Medical Research Inc
find a trial
General Registration

Can’t find a trial? Not sure which trial to choose? Complete a general registration and we’ll contact you with suitable trials.

Register
filter trials
Skip to content